

HALF-YEAR INVESTOR CONFERENCE CALL

Acrux (ASX: ACR) invites investors and interested parties to a conference call to discuss the results for the half-year ended 31 December 2017.

Investor Conference Call details:

Date: **Wednesday 21 February 2018**

Time: **10:00am (AEDT)**

Conference ID: **2475239**

Dial-in Details:

Toll Free Dial-in Details: 1800 123 296

Australia: +61 2 8038 5221

New Zealand 0800 452 782

Singapore 800 616 2288

United States 1855 293 1544

United Kingdom 0808 234 0757

A Q&A session will be held following the Company presentation. Shareholders and analysts are encouraged to participate by forwarding questions to investor@acrux.com.au in advance of the conference call.

Acrux recommends participants dial in prior to the commencement of the call. A recording of the call will be made available in the 'Investor Centre' section of the Company website at: <http://www.acrux.com.au/>

For further information, contact

Michael Kotsanis, CEO and Managing Director: 03 8379 0100

About Acrux

Acrux (ASX: ACR) is a pharmaceutical company dedicated to developing and commercialising topical pharmaceuticals. Incorporated in 1998 and using in house facilities and capabilities, Acrux has successfully developed and commercialised through licensees a number of topically applied pharmaceutical products in the US and Europe. Acrux is currently developing of a range of generic products for the US market by leveraging its on-site laboratories, GMP manufacturing suite, clinical and commercial experience to bring affordable products to market. Acrux encourages collaboration and is well positioned to discuss partnering and product development.

For further information on Acrux, visit www.acrux.com.au

